LUNG CANCER: The FDA have approved the MET inhibitor capmatinib for advanced NSCLC harbouring MET exon 14 skipping. Approval is based on ORR of 68% and 41% for treatment-naive and previously treated patients, respectively.

Web

May 11, 2020

SCIENTIFIC

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer